NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · BLFS · USD
Stock price, earnings
Quote as of Oct 5, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BioLife Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioLife Solutions, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioLife Solutions, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $0.04+233.33% vs estimate | $23.94M+7.74% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | -$0.01+83.33% vs estimate | $22.71M+4.79% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.02+77.78% vs estimate | $30.57M+19.71% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $31.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$416.67+$13.03 (+3.23%)
West Pharmaceutical Services, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.93% below the high.
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$8.46-$0.04 (-0.47%)
Maravai LifeSciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
$41.27+$0.64 (+1.58%)
Azenta, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.08% below the high.
$18.29-$0.35 (-1.88%)
Cryoport, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.12% below the high.
$8.09+$0.23 (+2.93%)
Alpha Teknova, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.66% below the high.
